Business Context and Reporting Period
Damora Therapeutics, Inc. (DMRA) filed this Form 8-K on June 17, 2026, to report the results of its 2026 Annual Meeting of Stockholders held on the same date. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of four proposals submitted to stockholders. A quorum was established with 55,009,938 shares represented out of 60,303,212 shares outstanding on the record date of April 22, 2026.
- Election of Directors: Michael Landsittel and Cameron Turtle, D.Phil, were elected as Class III directors. Both nominees received over 51.4 million votes "For" with approximately 29,000 votes "Withheld."
- Say-on-Pay: The advisory vote to approve executive compensation was approved with 51,401,988 votes "For," 3,546 "Against," and 27,018 "Abstain."
- Say-on-Frequency: Stockholders voted for an annual frequency for future Say-on-Pay votes. The "1 Year" option received 50,913,167 votes, significantly outpacing the "3 Years" option (518,015 votes). The Board has determined to hold future Say-on-Pay votes annually.
- Ratification of Auditor: The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 54,977,317 votes "For."
Guidance, Outlook, and Risks
This filing does not contain management commentary on business outlook, financial guidance, risk factors, or contingencies. It strictly reports the administrative results of the Annual Meeting.
Key Facts for Investor Verification
- Verify the full text of the Definitive Proxy Statement (Schedule 14A) filed on April 29, 2026, for detailed background on the director nominees and executive compensation.
- Confirm the company's financial health and cash runway through its most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Note that the Board has committed to annual Say-on-Pay votes based on the stockholder preference expressed in this filing.